Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data-Reference-Cited by-同舟云学术

Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data

Published:2016-02-23 Issue:3 Volume:68 Page:308-317
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Alemao Evo¹,Joo Seongjung²,Kawabata Hugh²,Al Maiwenn J.³,Allison Paul D.⁴,Rutten‐van Mölken Maureen P. M. H.³,Frits Michelle L.⁵,Iannaccone Christine K.⁵,Shadick Nancy A.⁵,Weinblatt Michael E.⁵

Affiliation:

1. Bristol‐Myers SquibbPrinceton New Jersey

2. Bristol‐Myers SquibbHopewell New Jersey

3. Institute of Health Policy and Management and Institute for Medical Technology Assessment, Erasmus UniversityRotterdam The Netherlands

4. University of PennsylvaniaPhiladelphia

5. Brigham and Women's Hospital and Harvard Medical SchoolBoston Massachusetts

Funder

The Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) Registry

Crescendo Bioscience

UCB

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.22678

Reference43 articles.

1. Rheumatoid arthritis

2. Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?

3. Societal cost of rheumatoid arthritis patients in the US

4. Centers for Disease Control and Prevention. Arthritis-related statistics. 2016. URL:http://www.cdc.gov/arthritis/data_statistics/arthritis-related-stats.htm.

5. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor;Advances in Therapy;2024-08-07

2. Intended and unintended consequences of strategies to meet performance benchmarks for rheumatologist referrals in a centralized intake system;Journal of Evaluation in Clinical Practice;2023-09-18

3. A Narrowing Mortality Gap: Temporal Trends of Cause‐Specific Mortality in a National Matched Cohort Study in US Veterans With Rheumatoid Arthritis;Arthritis Care & Research;2023-01-25

4. Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials;Rheumatology Advances in Practice;2022-12-30

5. Development of an interdisciplinary early rheumatoid arthritis care pathway;BMC Rheumatology;2022-06-25